Savara Inc
NASDAQ:SVRA
Savara Inc
Net Issuance of Common Stock
Savara Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Net Issuance of Common Stock
$127.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.5B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$728m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
-$200m
|
CAGR 3-Years
66%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-78%
|
CAGR 10-Years
N/A
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
127.4m
USD
Based on the financial report for Sep 30, 2024, Savara Inc's Net Issuance of Common Stock amounts to 127.4m USD.
What is Savara Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
24%
Over the last year, the Net Issuance of Common Stock growth was 70%. The average annual Net Issuance of Common Stock growth rates for Savara Inc have been 2% over the past three years , 34% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet